Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Sep 24;100(38):e27223.
doi: 10.1097/MD.0000000000027223.

Prognostic significance of platelet lymphocyte ratio in patients with melanoma: A meta-analysis

Enwen Wang  1 , Hui Huang  2 , Long Tang  3 , Ling Tian  1 , Liejun Yang  1 , Sixiong Wang  1 , Huiwen Ma  4
Affiliations
Meta-Analysis

Prognostic significance of platelet lymphocyte ratio in patients with melanoma: A meta-analysis

Enwen Wang et al. Medicine (Baltimore). .

Abstract

Background: The aim of this study was to systematically evaluate the prognostic role of platelet lymphocyte ratio (PLR) in patients with melanoma through performing a meta-analysis.

Methods: PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure were searched for potential studies. The basic characteristics and relevant data were extracted. Hazard ratios with 95% confidence intervals (CIs) were pooled to evaluate the prognostic role of PLR in patients with melanoma.

Results: Ten studies enrolling 2422 patients were included. The pooled hazard ratios of higher PLR for overall survival and progression-free survival in melanoma were 1.70 (95% CI, 1.22-2.37) and 1.65 (95% CI, 1.10-2.47), respectively. Sensitivity analysis and subgroup analyses were also performed. No significant publication bias was observed.

Conclusion: Our results showed that higher PLR was associated with poorer overall survival and progression-free survival in patients with melanoma. These findings may help to determine the prognosis and explore future novel therapies based on modulating inflammation and immune responses in melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Selection process of the studies.
Figure 2
Figure 2
Pooled HR of higher PLR for (A) OS and (B) PFS in patients with melanoma. HR = hazard ratio, OS = overall survival, PFS = progression-free survival, PLR = platelet lymphocyte ratio.
Figure 3
Figure 3
The Begg plots of publication bias of the studies for (A) OS and (B) PFS. OS = overall survival, PFS = progression-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Coit DG, Thompson JA, Albertini MR, et al. . Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17:367–402. - PubMed
    1. Richtig E. ASCO Congress 2018: melanoma treatment. Memo 2018;11:261–5. - PMC - PubMed
    1. O’Neill CH, Scoggins CR. Melanoma. J Surg Oncol 2019;120:873–81. - PubMed
    1. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol 2020;18:197. - PMC - PubMed